doi: 10.1016/s0960-894x(01)00344-4.
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
Affiliations
- PMID: 11459659
- DOI: 10.1016/s0960-894x(01)00344-4
Item in Clipboard
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
Bioorg Med Chem Lett.
.
Abstract
This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compounds. ZD1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours. In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.
Similar articles
-
Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.Int J Cancer. 2002 Mar 10;98(2):310-5. doi: 10.1002/ijc.10173. Int J Cancer. 2002. PMID: 11857424
-
Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).Mol Cancer Ther. 2003 Apr;2(4):345-51. Mol Cancer Ther. 2003. PMID: 12700278
-
Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").Br J Cancer. 2002 May 6;86(9):1518-23. doi: 10.1038/sj.bjc.6600299. Br J Cancer. 2002. PMID: 11986789 Free PMC article.
-
Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.Semin Oncol. 2001 Oct;28(5 Suppl 16):56-66. doi: 10.1016/s0093-7754(01)90283-0. Semin Oncol. 2001. PMID: 11706397 Review.
-
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.Semin Oncol. 2002 Feb;29(1 Suppl 4):37-46. doi: 10.1053/sonc.2002.31521. Semin Oncol. 2002. PMID: 11894012 Review.
Cited by
-
Ten things you should know about protein kinases: IUPHAR Review 14.Br J Pharmacol. 2015 Jun;172(11):2675-700. doi: 10.1111/bph.13096. Epub 2015 Mar 24. Br J Pharmacol. 2015. PMID: 25630872 Free PMC article. Review.
-
Hybrid Pharmacophore- and Structure-Based Virtual Screening Pipeline to Identify Novel EGFR Inhibitors That Suppress Non-Small Cell Lung Cancer Cell Growth.Int J Mol Sci. 2022 Mar 23;23(7):3487. doi: 10.3390/ijms23073487. Int J Mol Sci. 2022. PMID: 35408854 Free PMC article.
-
Gefitinib.Drugs. 2002;62(15):2237-48; discussion 2249-50. doi: 10.2165/00003495-200262150-00008. Drugs. 2002. PMID: 12381224 Review.
-
Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib.Cancer Cell Int. 2008 Jan 4;8:1. doi: 10.1186/1475-2867-8-1. Cancer Cell Int. 2008. PMID: 18177496 Free PMC article.
-
How were new medicines discovered?Nat Rev Drug Discov. 2011 Jun 24;10(7):507-19. doi: 10.1038/nrd3480. Nat Rev Drug Discov. 2011. PMID: 21701501 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Research Materials
